... for a 1.25 credit. Comments: Rolling out the short call aspect of my XBI covered call at ~50% max to the June expiry for a 1.25 credit. Cost basis now 85.94 (See Post Below) minus 1.25 or 84.69.
Alpine is a biotech stock that had an earnings report beating estimates two weeks ago. It is now reaching for all-time highs. That said, it is burning cash just slowing down the burn. Both revenue and earnings showed remarkable improvement as compared with the previous quarter. The bullish momentum of price and volume is obvious on the weeky chart with the...
HIMS had an excellent earnings report for a small cap company; it is consumer driven quality focused and helps the customer feel good about him/her- self. It does not have any gender orientation agenda nor any obvious political inclinations. On the 120 minute chart, it started a moving averge convergence about a week before earnings. The Greeny TTM...
... for a 1.90 credit. Comments: Selling a put here, since the resulting cost basis if assigned shares would be lower than the cost basis of the position I've currently got on now. The full position is now a June 21st 82/88 covered strangle (i.e., short put, stock, short call). Will look to take profit at 50% max. Metrics: Buying Power Effect/Break Even/Cost...
... for an 85.94 debit. Comments: 32.5% 30-Day IV. Buying a one lot and selling a -75 delta call against to emulate a 25 short put, take advantage of call side IV skew, and to have built-in defense via the short call. Metrics: Cost Basis/Break Even/Buying Power Effect: 85.94 Delta/Theta: 28.5/4.31 Max Profit: 2.06 ($206) ROC at Max: 2.40% ROC at 50% Max:...
LCTX on the weekly chart here has been falling since late 2021 and found support at the bottom of the high volume area of the volume profile and ranged between it and the POC line for the past 18 months. The is a high end clinically active biotechnology firm using stem cells to produce therapeutic cell lines . ( One experiment using the mammary glands of...
Biotechnology is expected to be a hot subsector this year as healthcare recovered further from the COVID pandemic anything from startups to big pharma- from vaccines to new drugs for diabetes, liver disease and obesity. This is shown on a weekly chart to show the long term trend with XBI pivoting to bullish back in early November. I add long positions when I...
IRTC on the weekly chart shows a symmetrical triangle with compression of price into the apex confluent with the 5 year anchored mean VWAP. I am very familiar with the product line including often lifesaving technology such as AEDs. The company has had weak earnings reports but price has managed to so from undervalued to fair value. I will add to my...
ABT on the one-hour chart is in a sideways diverging channel with Bollinger Bands overlaid and now compressing. In Europe, the new implantable cardiac monitor has tentative approval producing a growth narrative. Relative volumes and volatility have decreased heading into the pivot. ABT is in what is projected to be one of the hottest sectors this year. It pays...
VINC was a penny stock and is now in the near penny category as this biotech stock has had a great run in the past 10 days. On the 30 minute chart, 225 shares are bought at low prices and 125 shares are sold for profit with 100 shares still running as the momentum slows. Overall, the trades where profitable averaging 12% daily in an average trade of 4.5...
VINC went from 1.5 to 3.0 in less than three hours with 12X relative volume in the afternoon after a month of a slow climb from a news release that really did not amount to much. Insiders are 25% of the shareholders and that may be the story here. This could be manipulation at its finest. I have to wonder how many insiders bought how many shares and when the...
VTYX is an illustrative case in the trend is your friend. VTTX warmed up on Frbruary 20th and went parabolic on the next day and then faded while the moving averages and VWAP lines caught up. This is a buyable dip. It has now printed a couple of engulfing bullish candles. VTYX did less than a full 0.5 retracement as a sign of strength. I will take a long...
Quantum-Si NASDAQ:QSI , develops access to the proteome with single-molecule analysis and democratizing to researchers & clinicians Also, "is the world’s first-to-market provider of protein sequencing instruments with core technology based on proprietary time-domain sequencing that enables resolution of amino acids during experiments".- Ark Invest The stock is...
EPIX on the 15-minute chart shows a solid trend up with a set of moving averages as the guardrails now in a bit of a pullback. The after-hours price action will not appear on the chart but price jumped 5%. Earnings are anticipated for 2/8 or 2/9 as best as I can tell. Internet search information is not consistent. So, if tomorrow this is still pre-earnings...
BLUE a week ago had a bull run to gain 90% in 5 days and then reversed into a standard Fibonacci retracement on the 30-minute chart, then in consolidation for a day or two getting support from the mean anchored VWAP. The last trading day was a quick rise with momentum in a bull flag. Earnings are coming. I will take another long trade on BLU into earnings....
LEXX on the daily chart is on a big bullrun breaking out of an ascending broadening triangle or megaphone pattern demostrative of increasing volatility. Retlative volumes are 2X the historical comparison. Price is now on the approach to the highs of 2023 but is only 15% of the all high highs of 19 at the neckline of a head and shoulders back in 2018-2019,...
VERX on the 15 minute chart demonstrates printing a high tight bull flag pattern in its bullrun after the earnings report was a two line beat much like the one a quarter ago. VERX has impressed traders including this one who got in on the ride early. I will trade this like others recently with a similar pattern. I will hold during the consolidation and watch...
Today NVAX is selling for a tiny fraction of its all-time high as shown in a previous idea. Earnings is coming this upcoming week. This week NVAX news release showed it had settled a years long litigation over a failed COVID. In the face of earnings around the corner, was this news release a coincidence or instead a case of excellent executive and legal...